Hutchmed to present new and updated clinical trial data

The AIM-traded firm said the presentations would showcase results from studies of several compounds developed by the company, focusing on lung and gastrointestinal cancers.

At WCLC24, Hutchmed said it would present findings from the ‘FLOWERS’ study, a phase two clinical trial investigating the combination of osimertinib and savolitinib in patients with advanced EGFR-mutated, MET-aberrant non-small cell lung cancer (NSCLC).

Preliminary data from the study, which included two cohorts of patients, showed that the combination therapy in cohort two achieved significantly better outcomes than osimertinib monotherapy in cohort one.

The confirmed objective response rate (ORR) was 90.5% in the combination group compared to 60.9% in the monotherapy group.

Additionally, the combination therapy led to a higher disease control rate (DCR) of 95.2%, compared to 87% with osimertinib alone.

Although progression-free survival (PFS) data was still immature, Hutchmed said the early results favoured the combination therapy, with a median progression-free survival of 19.6 months compared to 9.3 months for monotherapy.

The safety profiles of both treatments were found to be manageable and in line with expectations.

Hutchmed said it would also present further analyses from other key trials at the ESMO Congress 2024, including data from the FRESCO-2 study of fruquintinib in metastatic colorectal cancer and the FRUTIGA study in gastric cancer.

A biomarker study of savolitinib in gastric cancer and investigator-initiated studies involving fruquintinib and surufatinib would also be featured.

At 1054 BST, shares in Hutchmed China were up 0.76% at 264p.

Reporting by Josh White for Sharecast.com.